Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Year Ended December 31,
	2020			2019
Numerator
Net loss - before noncontrolling interest	$	(35,888	)	$	(17,268	)
Net loss attributable to noncontrolling interest		1,612			811
Net loss - as reported, attributable to PAVmed Inc.	$	(34,276	)	$	(16,457	)
Series B Convertible Preferred Stock dividends – earned(1)	$	(287	)	$	(270	)
Net loss attributable to PAVmed Inc. common stockholders	$	(34,563	)	$	(16,727	)
Denominator
Weighted average common shares outstanding, basic and diluted(2)		47,432,115			30,197,458
Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.72	)	$	(0.54	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.73	)	$	(0.55	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

	December 31,
	2020		2019
PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards		8,215,195		5,903,529
Unit purchase options - as to shares of common stock		53,000		53,000
Unit purchase options - as to shares underlying Series Z Warrants		53,000		53,000
Series Z Warrants		16,814,939		16,815,039
Series W Warrants		381,818		381,818
Series B Convertible Preferred Stock(3)		1,228,075		1,158,209
Total		26,746,027		24,364,595

(1)	The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented.
(2)	Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2020 and 2019 include the shares of the Company issued and outstanding during the years ended December 31, 2020 and December 31, 2019, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
(3)	If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a corresponding number of additional outstanding shares of common stock of the Company.